<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>27888860</identifier>
<setSpec>0210-5705</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Chaparro, María</dc:author>
<dc:description xml:lang="en">Inflammatory bowel disease is a chronic disorder of unknown aetiology that results from a pathologic response from both the innate and acquired immune systems, leading to chronic inflammation of the gastrointestinal tract. New drugs have been introduced into the therapeutic armamentarium of inflammatory bowel disease but are not effective in all patients; moreover, among initial responders, there have been reports of loss of response over time. In addition, these drugs sometimes have adverse effects and are often expensive. The present article reviews the studies presented at Digestive Disease Week 2016 that provided new data on the optimisation of currently approved treatments for inflammatory bowel disease, experience with recently approved drugs in clinical practice, and some studies on molecules that are under development for the treatment of these diseases.</dc:description>
<dc:type>Journal Article</dc:type>
<dc:language>es</dc:language>
<dc:subject>Enfermedad de Crohn</dc:subject>
<dc:subject>Immunosuppressants</dc:subject>
<dc:subject>Anti-TNF</dc:subject>
<dc:subject>Enfermedad inflamatoria intestinal</dc:subject>
<dc:subject>Faecal transplant</dc:subject>
<dc:subject>Biosimilar</dc:subject>
<dc:subject>Inflammatory bowel disease</dc:subject>
<dc:subject>Crohn disease</dc:subject>
<dc:subject>Inmunosupresores</dc:subject>
<dc:subject>Treatment</dc:subject>
<dc:subject>Tofacitinib</dc:subject>
<dc:subject>Trasplante fecal</dc:subject>
<dc:subject>Stem cells</dc:subject>
<dc:subject>Tratamiento</dc:subject>
<dc:subject>Colitis ulcerosa</dc:subject>
<dc:subject>Vedolizumab</dc:subject>
<dc:subject>Células madre</dc:subject>
<dc:subject>Ulcerative colitis</dc:subject>
<dc:date>2016 Sep </dc:date>
<dc:title xml:lang="es">Tratamiento de la enfermedad inflamatoria intestinal: lo nuevo de la Digestive Disease Week 2016.</dc:title>
<dc:title xml:lang="en">Treatment of inflammatory bowel disease: what's new in Digestive Disease Week 2016.</dc:title>
<dc:publisher>Gastroenterologia y hepatologia</dc:publisher>
</metadata>
</record>
</pubmed-document>
